Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T Cells (GD2CART) for H3K27M-mutant Diffuse Midline Glioma (DMG)
Stanford University
Summary
The primary purpose of this study is to test whether CAR T cells targeting GD2 (GD2CART) can be successfully made and safely given to children and adults with H3K27M-mutant diffuse midline glioma (DMG). Eligible subjects may have DMG arising in the pons (called difuse intrinisic pontine glioma, DIPG), the spinal cord, or other areas of the brain such as a thalamus
Description
Primary Objectives: * Determine the feasibility of manufacturing autologous T cells transduced with 14g2a-CD8-BBz-iCasp9 retroviral vector expressing GD2 Chimeric Antigen Receptor (GD2CART) for administration in subjects with H3K27M-mutant diffuse midline glioma (DMG) using a retroviral vector and dasatinib in the Miltenyi CliniMACS Prodigy® system. * Assess the safety and identify the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), route and schedule of GD2CART and lymphodepleting chemotherapy in subjects with H3K27M-mutant DMG. * Assess the safety of the MTD/RP2D, route…
Eligibility
- Age range
- 2–60 years
- Sex
- All
- Healthy volunteers
- No
INCLUSION CRITERIA 1. Disease Status: Diagnosis of H3K27M mutant diffuse midline glioma (DMG) 2. H3K27M or H3K27I mutation. Confirmed by CLIA test. 3. Age: Greater than or equal to 2 year of age and less than or equal to 60 years of age. 4. Prior Therapy: * At least 4 weeks following completion of standard upfront radiation therapy. * At least 3 weeks post chemotherapy or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy, except for systemic inhibitory/stimulatory immune checkpoint therapy that requires 3 months. * Dordaviprone (Modeyso), previou…
Interventions
- DrugGD2 CAR T cells
Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor
- DrugFludarabine
Fludarabine 30 mg/m2 per day IV for days -4, -3, -2
- DrugCyclophosphamide
Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2
- DrugRituximab
First round: 750 mg/m2 per day IV for days -6 and -5. Subsequent rounds: 750 mg/m2 per day IV for day -5.
Location
- Lucile Packard Children's Hospital (LPCH)Stanford, California